Compare ACADIA Pharmaceuticals Inc. (ACAD) vs LTC Properties Inc (LTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs LTC Properties Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while LTC Properties Inc trades at $39.4 (market cap $2.01B). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 2.2× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.81% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | LTC | |
|---|---|---|
Market Cap | $4.49B | $2.01B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $40.36 |
52-Week Low | $20.06 | $33.98 |
Enterprise Value | $3.69B | $2.86B |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
LTC Properties trades at $39.23, down 0.13% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.69, missing expectations of $0.72, but revenue grew to $263M in 2025. Analyst consensus is mixed with 27% buy ratings, while recent news highlights dividend declarations and a $54M SHOP acquisition, reinforcing its focus on senior housing investments.
Outlook remains supported by demographic trends in senior housing, though earnings misses and high debt levels pose risks. The stock offers a monthly dividend, but investors face headwinds from execution challenges in shifting to SHOP strategy and interest rate sensitivity due to substantial leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
